Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 205   

Articles published

VRX 13.45 -0.01 (-0.04%)
price chart
Valeant Pharmaceuticals International Inc swings to first profit in 6 quarters ...
Canada's Valeant Pharmaceuticals International Inc reported a first-quarter profit, compared with a year-ago loss, due to an income tax benefit, and the drugmaker also raised its full-year adjusted EBITDA forecast.
Valeant surges on adjusted earnings, but analysts remain wary  The Globe and Mail
Valeant Pharmaceuticals Intl Inc And Office Depot Inc Soar After Earnings ...  ValueWalk
What a Return to Profits for Valeant Pharmaceuticals Intl Inc. Means
The day that many investors thought would never come about again, at least not in any reasonable timeline, finally came this month, as Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) finally posted a profit. This was the first profit that Valeant ...
A Valeant Fight: Stock Gains 50%, Will The Rally Continue? - Valeant ...  Amigobulls
Go Long Valeant Pharmaceuticals Intl Inc (VRX) Stock for Free
An Update on the Solvency Issues at Valeant Pharmaceuticals Intl Inc.
Last week, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) reported earnings that finally surpassed expectations. Earnings per share came in at US$1.74, which is a significant step given that the company lost money for the same period a year ago.
Safirstein Metcalf LLP and HGT Law Updates Investors on Valeant ...  Stockhouse
5 More Reasons Valeant Pharmaceuticals Bottomed  Seeking Alpha
Valeant Pharmaceuticals International 'seriously' considers name change to ...
Chief Executive Officer Joe Papa said that Valeant Pharmaceuticals International Inc. is considering a name change after a two-year stretch that has seen the company lose more than 95 per cent of its value amid harsh criticism of its business practices ...
Valeant Announces 2017 Annual Meeting Results  Canada NewsWire (press release)
Drug-maker Valeant on course to debt repayment target: CEO  Reuters
Valeant Pharmaceuticals Intl Inc (VRX) Struggles with Generic Competition
Valeant Pharmaceuticals Intl Inc's (NYSE:VRX) Branded Rx division has been making headlines as the embattled drugmaker struggles to prevent generic competition from eroding the sales potential of several drugs in Salix.
Valeant Pharmaceuticals Intl Inc (VRX) Rating Reiterated by Wells Fargo & Co  Sports Perspectives
Does Valeant Pharmaceuticals International, Inc. (VRX)'s current closing ...  TopChronicle
What Canopy Growth Corp can Learn From Valeant Pharmaceuticals Intl Inc
In case you have yet to hear the news, please brace yourself. Shares of Valeant Pharmaceuticals Intl Inc (TSX:VRX)(NYSE:VRX) hit a new 52-week low this past Friday.
Valeant Pharmaceuticals Nearing Capitulation, Breaks $8.50  Seeking Alpha
Valeant Pharmaceuticals Intl Inc (VRX): A Company in Existential Crisis  Smarter Analyst
Jeff Ubben Buys Bioverativ Inc, Valeant Pharmaceuticals International Inc ...
Jeff Ubben added to the holdings in Valeant Pharmaceuticals International Inc by 20.03%. The purchase prices were between $10.64 and $16.86, with an estimated average price of $13.76.
Statement Regarding Xifaxan Intellectual Property Litigation
LAVAL, Quebec, May 17, 2017 /PRNewswire/ -- Salix Pharmaceuticals, Inc. and parent Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Actavis Laboratories, Inc., at Actavis' request, have agreed to stay outstanding ...
Valeant and Actavis agree to stay litigation relating to Valeant's top ...  MarketWatch
Valeant: Et Tu Mylan?
Valeant Pharmaceuticals (VRX -0.8%) is hovering over session lows on the news that Mylan (MYL +0.4%) has prevailed in challenging Valeant's U.S. Patent No. 8,865,688 covering UC med Apriso (mesalamine). The USPTO determined that claims 1 and 16 ...
Valeant Pharmaceuticals International, Inc. (VRX) held by 66 SEC 13F Filers  AppsforPCdaily
Valeant Pharmaceuticals International Stock Rise in 2016 Q4 Driven by ...  Finance News Daily
Valeant Announces Key Appointments In Dermatology And Corporate Communications ...
LAVAL, Quebec, May 5, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced appointments to the dermatology leadership team of Michael McMyne, who has joined as vice president of ...
Valeant Pharmaceuticals Intl Inc (VRX) Stock Won't Keep This Rally Up
Valeant Pharmaceuticals Intl Inc (VRX) Still on a Rocky Debt Road, Ocular ...  Smarter Analyst